Edwards Lifesciences Corp (EW) Stock AnalysisEWStock AnalysisEdwards Lifesciences Corp

Edwards Lifesciences Corporation is a global structural heart company. Its work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. TMTT category includes PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and SAPIEN M3 mitral valve replacement system. INSPIRIS RESILIA aortic valve offers RESILIA tissue and VFit technology. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Edwards Lifesciences is a good buy right now due to its current price of $90.21, which is well below the average analyst price target of $101.57, suggesting a potential upside of approximately 12.5%. Additionally, the forward P/E ratio of 29.94 indicates reasonable valuation considering its growth prospects. The main risk is the RSI at 45.688, which suggests the stock is nearing oversold territory, indicating potential volatility.

21 analysts cover EW: 16 rate it Buy, 4 Hold and 1 Sell. The average price target is 96.52.